Hereditary Haemorrhagic Telangiectasia
9
2
3
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
11.1%
1 terminated out of 9 trials
80.0%
-6.5% vs benchmark
0%
0 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (9)
Non-Invasive Detection of Pulmonary Right-to-Left Shunts Using the SONAS Ultrasound Device
Immunological Effects of Iron Supplementation in HHT Disease
Genotype Expression and Phenotype of Endothelial Cells, Carrying an ACVRL1, ENG or SMAD4 Mutation, in Response to BMP9 for the Identification of New Therapeutic Targets in Hereditary Haemorrhagic Telangiectasia
Evaluation of Video-assisted Instructions of Nasal Self-packing in Patients with HHT
Hereditary Haemorrhagic Telangiectasia Flight Safety Study
Iron Deficiency and Hereditary Haemorrhagic Telangiectasia
Vitamin D and Hereditary Haemorrhagic Telangiectasia
Recurrence of Hereditary Hemorrhagic Telangiectasia (HHT) After Liver Transplantation
Pulmonary Arteriovenous Malformations (PAVMs) in Hereditary Haemorrhagic Telangiectasia (HHT)